...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Chinese Herbal Medicine (Chaihu-Huaji Decoction) Alleviates Postembolization Syndrome following Transcatheter Arterial Chemoembolization and Improves Survival in Unresectable Hepatocellular Cancer: A Retrospective Study
【24h】

Chinese Herbal Medicine (Chaihu-Huaji Decoction) Alleviates Postembolization Syndrome following Transcatheter Arterial Chemoembolization and Improves Survival in Unresectable Hepatocellular Cancer: A Retrospective Study

机译:中草药(柴胡 - 华吉汤)减轻经截面动脉化疗栓塞后的后栓塞综合征,提高了不可切除的肝细胞癌的存活:回顾性研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective. To examine the efficacy of Chaihu-huaji decoction combined with transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC) patients. Methods. We retrospectively reviewed the data of 125 HCC patients treated in Chongqing Cancer Hospital between January 2012 and December 2014, including 64 patients who received Chaihu-huaji decoction and TACE (Chaihu-huaji group) and 61 patients who received only TACE (control group). The patients were examined until the last follow-up or death. Complications, hepatotoxicity, and nephrotoxicity were compared between the two groups. Results. Fever, nausea, vomiting, poor appetite, and leukocytopenia were alleviated in patients who received Chaihu-huaji decoction, and no cases of significant hepatic and renal toxicities related to the herbal medicine were observed in the Chaihu-huaji group. The 3-year overall survival probability was significantly higher in the Chaihu-huaji group (26.47%) than in the control group (13.06%). Conclusion. Chaihu-huaji decoction may prevent adverse events after TACE and prolong overall survival of unresectable HCC patients when combined with TACE.
机译:客观的。研究柴胡华吉汤与霉变化疗栓塞(TACE)在不可切除的肝细胞癌(HCC)患者中的疗效。方法。我们回顾性地审查了2012年1月和2014年12月在重庆癌症医院治疗的125株HCC患者的数据,其中64名接受柴胡华吉汤和TACE(柴湖 - 华吉集团)和61名仅收到TACE的患者(对照组)。检查患者直到最后一次后续或死亡。在两组之间比较并发症,肝毒性和肾毒性。结果。发烧,恶心,呕吐,差,白细胞病患者被培育柴胡华吉汤的患者缓解,在柴胡华吉集团中没有观察到与草药有关的显着肝癌和肾脏毒性。柴胡华吉组(26.47%)比对照组(13.06%)明显高出3年的总体存活概率。结论。 Chaihu-Huaji汤剂可以在结合TACE后延长TACE后的不良事件并延长未切除的HCC患者的整体存活。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号